Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Respir Crit Care Med. 2009 Jan 1;179(1):11-8. doi: 10.1164/rccm.200805-737OC. Epub 2008 Oct 23.

Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study.

Author information

1
School of Translational Medicine, University of Manchester, Manchester, UK. ddenning@manchester.ac.uk

Erratum in

  • Am J Respir Crit Care Med. 2009 Feb 15;179(4):330-1.

Abstract

RATIONALE:

Some patients with severe asthma are immunologically sensitized to one or more fungi, a clinical entity categorized as severe asthma with fungal sensitization (SAFS). It is not known whether SAFS responds to antifungal therapy.

OBJECTIVES:

To evaluate the response of SAFS to oral itraconazole.

METHODS:

Patients with severe asthma sensitized to at least one of seven fungi by skin prick or specific IgE testing were recruited. All had total IgE less than 1,000 IU/ml and negative Aspergillus precipitins. They were treated with oral itraconazole (200 mg twice daily) or placebo for 32 weeks, with follow-up for 16 weeks.

MEASUREMENTS AND MAIN RESULTS:

The primary end point was change in the Asthma Quality of Life Questionnaire (AQLQ) score, with rhinitis score, total IgE, and respiratory function as secondary end points. Fifty-eight patients were enrolled, of whom 41% had been hospitalized in the previous year. Baseline mean AQLQ score was 4.13 (range, 1-7). At 32 weeks, the improvement (95% confidence interval) in AQLQ score was +0.85 (0.28, 1.41) in the antifungal group, compared with a -0.01 (-0.43, 0.42) change in the placebo group (P = 0.014). Rhinitis score improved (-0.43) in the antifungal, and deteriorated (+0.17) in the placebo group (P = 0.013). Morning peak flow improved (20.8 L/minute, P = 0.028) in the antifungal group. Total serum IgE decreased in the antifungal group (-51 IU/ml) but increased in placebo group (+30 IU/ml) (P = 0.001). No severe adverse events were observed, but seven patients developed adverse events requiring discontinuation, five in the antifungal group.

CONCLUSIONS:

SAFS responds to oral antifungal therapy as judged by large improvements in quality of life in about 60% of patients.

PMID:
18948425
DOI:
10.1164/rccm.200805-737OC
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center